Search research articles
Contact Us
Filters
Showing results (121-130 of 161) with videos related to
Page
of 17
Sort By:
Blood Cancer Journal
|
April 12, 2024
Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium
Aimaz Afrough, Hamza Hashmi, Doris K Hansen, et al.
American Journal of Hematology
|
March 21, 2026
The Safety and Efficacy of Commercial BCMA-Directed CAR T-Cell Therapy in Systemic AL Amyloidosis With Concurrent Myeloma
Matthew J Rees, Raffaella Cassano Cassano, Melinda Tan, et al.
American Journal of Hematology
|
October 11, 2025
Predictors of Delayed Responses to Teclistamab in Multiple Myeloma After Initial Non-Response
Rahul Banerjee, Gurbakhash Kaur, Beatrice M Razzo, et al.
Blood Advances
|
October 19, 2023
Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy
Lauren C Peres, Laura B Oswald, Christen M Dillard, et al.
Blood Cancer Journal
|
December 5, 2024
Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy
Maximilian Merz, Danai Dima, Hamza Hashmi, et al.
Blood
|
October 4, 2024
Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma
Surbhi Sidana, Krina K Patel, Lauren C Peres, et al.
Blood Advances
|
August 28, 2025
Safety and Efficacy of BCMA directed Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Plasma Cell Leukemia
Gliceida M Galarza Fortuna, Lauren C Peres, Elena Nazarenko, et al.
Haematologica
|
July 10, 2025
Cytopenias and infections following ciltacabtagene autoleucel in heavily-pretreated relapsed or refractory multiple myeloma
Danai Dima, Jennifer M Logue, Syed Hamza Bin Waqar, et al.
Blood Cancer Journal
|
March 28, 2026
Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium
Andrew J Portuguese, James A Davis, Shahzad Raza, et al.
Blood Cancer Journal
|
June 25, 2025
Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium
Danai Dima, Mariola A Vazquez-Martinez, James A Davis, et al.
Page
of 17
Search research articles
Search
Showing results (121-130 of 161) with videos related to
Sort By:
Page
of 17
Blood Cancer Journal
|
April 12, 2024
Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium
Aimaz Afrough, Hamza Hashmi, Doris K Hansen, et al.
American Journal of Hematology
|
March 21, 2026
The Safety and Efficacy of Commercial BCMA-Directed CAR T-Cell Therapy in Systemic AL Amyloidosis With Concurrent Myeloma
Matthew J Rees, Raffaella Cassano Cassano, Melinda Tan, et al.
American Journal of Hematology
|
October 11, 2025
Predictors of Delayed Responses to Teclistamab in Multiple Myeloma After Initial Non-Response
Rahul Banerjee, Gurbakhash Kaur, Beatrice M Razzo, et al.
Blood Advances
|
October 19, 2023
Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy
Lauren C Peres, Laura B Oswald, Christen M Dillard, et al.
Blood Cancer Journal
|
December 5, 2024
Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy
Maximilian Merz, Danai Dima, Hamza Hashmi, et al.
Blood
|
October 4, 2024
Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma
Surbhi Sidana, Krina K Patel, Lauren C Peres, et al.
Blood Advances
|
August 28, 2025
Safety and Efficacy of BCMA directed Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Plasma Cell Leukemia
Gliceida M Galarza Fortuna, Lauren C Peres, Elena Nazarenko, et al.
Haematologica
|
July 10, 2025
Cytopenias and infections following ciltacabtagene autoleucel in heavily-pretreated relapsed or refractory multiple myeloma
Danai Dima, Jennifer M Logue, Syed Hamza Bin Waqar, et al.
Blood Cancer Journal
|
March 28, 2026
Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium
Andrew J Portuguese, James A Davis, Shahzad Raza, et al.
Blood Cancer Journal
|
June 25, 2025
Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium
Danai Dima, Mariola A Vazquez-Martinez, James A Davis, et al.
Page
of 17